Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F21%3A00544774" target="_blank" >RIV/61388963:_____/21:00544774 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=11059775B2&KC=B2&FT=D&ND=4&date=20210713&DB=&locale=en_EP" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=11059775B2&KC=B2&FT=D&ND=4&date=20210713&DB=&locale=en_EP</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
Original language description
Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US11059775
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Jul 13, 2021
Owner name
The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence